Antibodies in infectious diseases: Polyclonals, monoclonals and niche biotechnology

New Biotechnology

Volumn 28, Issue 5, 2011, Pages 489-501

  Berry, Jody D ^a   Gaudet, Ryan G ^b  

^a Cangene Corporation   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DISEASE; CHRONIC DISEASE; COST EFFECTIVE; COST-OF-GOODS; DEFENSE MECHANISM; ECONOMIC SENSE; IMMUNOTHERAPEUTICS; INFECTIOUS AGENTS; INFECTIOUS DISEASE; MONOCLONAL ANTIBODIES (MAB); POLYCLONAL; REDUCING COSTS; SMALL MOLECULE INHIBITOR; VACCINE DEVELOPMENT;

ANTIBIOTICS; INDUSTRY; INNOVATION; MONOCLONAL ANTIBODIES; VACCINES; VIRUSES;

DISEASES;

ALBUMIN; ANTIBIOTIC AGENT; ANTIGEN; ANTIINFECTIVE AGENT; CEFALOTIN; CEFAMANDOLE; CEFTAZIDIME; EPITOPE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LAMIVUDINE; METRONIDAZOLE; MEZLOCILLIN; MONOCLONAL ANTIBODY; NEUROTOXIN; PENICILLIN G; PIPERACILLIN; POLYCLONAL ANTIBODY; POLYCLONAL HYPERIMMUNE IMMUNOGLOBULIN; POLYCLONAL IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VACCINE; VANCOMYCIN; VIRULENCE FACTOR;

BACILLUS ANTHRACIS; BIOTECHNOLOGY; CANDIDA; CHLAMYDIA TRACHOMATIS; CHRONIC DISEASE; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONVALESCENCE; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS INDUCED PNEUMONITIS; DEFENSE MECHANISM; DENGUE VIRUS; DIPHTHERIA; DRUG APPROVAL; DRUG COST; DRUG POTENCY; EBOLA HEMORRHAGIC FEVER; ENDEMIC DISEASE; ENTEROCOLITIS; EPIDEMIC MENINGITIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFECTION; INFLUENZA A; KLEBSIELLA PNEUMONIAE INFECTION; MIXED INFECTION; MOLECULE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NATURAL HOST; NEWBORN SEPSIS; NIPAH VIRUS; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PATHOGENESIS; PNEUMOCYSTIS CARINII; PNEUMONIA; PRIORITY JOURNAL; PROTECTION; PROTEUS INFECTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PURIFICATION; REVIEW; RICINUS COMMUNIS; STAPHYLOCOCCAL TOXIC SHOCK SYNDROME; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TECHNOLOGY; TOXIC SHOCK SYNDROME; VACCINIA; VARICELLA ZOSTER VIRUS; VIBRIO CHOLERAE; VIRUS; VIRUS NEUTRALIZATION; YERSINIA PESTIS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES; BIOTECHNOLOGY; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC TECHNIQUES; MODELS, IMMUNOLOGICAL;

BACTERIA (MICROORGANISMS);

EID: 80052790031     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.03.018     Document Type: Review

References (145)

1. Milestones in Microbiology: 1556 to 1940 1998, ASM Press. T.D. Brock (Ed.).
2. Saylor C., et al. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27S:G38-G46.
3. Marasco W.A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 2007, 25:1421-1434.
4. SARS a Case Study in Emerging Infections 2005, Oxford University Press, New York. A.R. McLean (Ed.).
5. Lowy I., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 2010, 362:197-205.
6. Beerli R.R., Rader C. Mining human antibody repertoires. MAbs 2010, 2:365-378.
7. Berry J.D. Rational monoclonal antibody development to emerging pathogens, biothreat agents and foreign animal disease: the antigen scale. Vet. J. 2005, 170:193-211.
8. Burton D.R., et al. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 2001, 260:109-143.
9. Imai M., et al. Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res. 1998, 53:129-139.
10. Webster R.G., Laver W.G. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J. Immunol. 1967, 99:49-55.
11. Moragues M.D., et al. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 2003, 71:5273-5279.
12. McClelland E.E., et al. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J. Clin. Invest. 2010, 120:1355-1361.
13. Orange J.S., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology. J. Allergy Clin. Immunol. 2006, 117:S524-S553.
14. ter Meulen J. Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opin. Emerg. Drugs 2007, 12:525-540.
15. Plotkin S. Countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 2008, 46:129-136.
16. Couderc T., et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009, 200:516-523.
17. Wu H., et al. Immunoprophylaxis of RSV infection: advancing from RSV-IVIG to palivizumab and motavizumab. Curr. Top. Microbiol. Immunol. 2008, 317:103-123.
18. Casadevall A., Scharff M.D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 1995, 21:150-161.
19. Burdick M.D., et al. Clearance of prions during plasma protein manufacture. Transfus Med. Rev. 2006, 20:57-62.
20. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Progress 2005, 21:11-16.
21. Salfeld J.G. Isotype selection in antibody engineering. Nat. Biotechnol. 2007, 25:1369-1372.
22. Johnson S., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 2010, 176:1215-1224.
23. Beck A., et al. Therapeutic antibodies and related products: choosing the right structure for success. Med. Sci. (Paris) 2009, 12:1024-1032.
24. Dechant M., et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002, 100:4574-4580.
25. Lendvai N., et al. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J. Immunol. 2000, 164:4367-4374.
26. Sarvas H., et al. Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Infect. Immunol. 1990, 2:317-332.
27. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 2007, 7:1401-1413.
28. van der Zee J.S., et al. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J. Immunol. 1986, 137:3566-3571.
29. Spiegelberg H.L. Biological role of different antibody classes. Int. Arch. Allergy Appl. Immunol. 1989, 90:22-57.
30. Horn M.P., et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob. Agents Chemother. 2010, 54:2338-2344.
31. Tchoudakova A., et al. High level expression of functional human IgMs in human PER.C6® cells. MAbs 2009, 1:1-9.
32. Ye J., et al. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin. Vaccine Immunol. 2010, 17:1363-1370.
33. Chen K., et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat. Immunol. 2009, 10:889-898.
34. Beenhouwer D.O., et al. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3 protect mice against Cryptococcus neoformans. Infect. Immun. 2007, 75:1424-1435.
35. Westerman F.E., et al. Serum IgG mediates mucosal immunity against rotavirus infection. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7268-7273.
36. Lazar G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4005-4010.
37. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8:226-234.
38. Taylor R.P., et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J. Immunol. 1997, 159:4035-4044.
39. Lindorfer M.A., et al. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J. Immunol. 2001, 167:2240-2249.
40. Dadachova E., et al. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10942-10947.
41. Dadachova E., et al. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J. Nucl. Med. 2004, 45:313-320.
42. Dadachova E., et al. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob. Agents Chemother. 2004, 48:1624-1629.
43. Little S.J., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 2002, 347:385-394.
44. Velicer C.M., et al. Antibiotic use in relation to the risk of breast cancer. JAMA 2004, 291:827-835.
45. Kozyrsky A.J., et al. Increased risk of childhood asthma from antibiotic use in early life. Chest 2007, 131:1753-1759.
46. Pai J.C., et al. Progress towards recombinant anti-infective antibodies. Recent Pat. Antiinfect. Drug Discov. 2009, 4:1-17.
47. Guo F., et al. Breaking the one antibody-one target axiom. Proc. Natl. Acad. Sci. U.S.A. 2006, 29:11009-11014.
48. Popkov M., et al. Instant immunity through chemically programmable vaccination and covalent self-assembly. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4378-4383.
49. Sepulveda J., et al. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect. Immun. 2010, 78:756-763.
50. Fattom A.S., et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in a hemodialysis patient. Vaccine 2004, 23:656-663.
51. Kaufman D. Veronate (Inhibitex). Curr. Opin. Invest. Drugs 2006, 7:172-179.
52. Hall A.E., et al. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect. Immun. 2003, 71:6864-6870.
53. Vernachio J., et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother. 2003, 47:3400-3406.
54. Bubeck Wardenburg J., et al. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 2007, 13:1405-1406.
55. Lorenz U., et al. Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy. Antimicrob. Agents Chemother. 2011, 55:165-173.
56. Kelly-Quintos C., et al. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect. Immun. 2006, 74:2742-2750.
57. Park J., et al. Infection control by antibody disruption of bacterial quorum sensing signalling. Chem. Biol. 2008, 14:1119-1127.
58. Neely A.N., et al. Passive anti-pcrv treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005, 31:153-158.
59. Imamura Y., et al. Effect of anti-pcrv antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur. Respir. J. 2007, 29:965-968.
60. Rachini A., et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 2007, 75:5085-5094.
61. Torosantucci A., et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 2005, 202:597-606.
62. Throsby M., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008, 4:e3942.
63. Sui J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
64. Sui J., et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 2008, 4:e1000197.
65. Rockx B., et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 2008, 82:3220-3235.
66. Shrestha B., et al. The development of therapeutic antibodies that neuralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010, 6:e1000823.
67. Radoshitzky S.R., et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 2007, 446:92-96.
68. Evans M.J., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
69. Glass W.G., et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 2005, 202:1087-1098.
70. Soares M.M., et al. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 2008, 14:1357-1362.
71. McKeating J.A., et al. Characterization of the HIV-1 neutralization escape mutants. AIDS 1989, 3:777-784.
72. Keck Z.Y., et al. Mutations in hepatitis C virus E2 located outsie the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J. Virol. 2009, 83:6149-6160.
73. Zharikova D., et al. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J. Virol. 2005, 79:6644-6654.
74. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 2007, 25:390-394.
75. Prabakaran M., et al. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 2009, 4:e5672.
76. Meulen J.T., et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006, 3:e237.
77. Seiler P., et al. In vivo selection of neutralization-resistant virus variants but no evidence of B cell tolerance in lymphocyttic choriomeningitis virus carrier mice expressing a transgenic virus-neutralizing antibody. J. Immunol. 2009, 162:4536-4541.
78. Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection. March 6, 2007. http://www.clinicaltrials.gov/show/NCT00300807.
79. Bregenholt S., et al. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr. Pharm. Des. 2007, 12:2007-2015.
80. Bakker A.B.H., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 2005, 79:9062-9068.
81. de Kruif J., et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu. Rev. Med. 2007, 58:359-368.
82. Goudsmit J., et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. 2006, 193:796-801.
83. Burton D.R., et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
84. Law M., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14:25-27.
85. White A.R., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003, 422:80-83.
86. Rhys Jones D., et al. A camelid anti-PrP antibody abrogates PrPSc replication in prion-permissive neuroblastoma cell lines. PLoS One 2010, 5:e9804.
87. Prescott W.A., et al. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010, 28:279-293.
88. Nielsen L.S., et al. Single-batch production of recombinant human polyclonal antibodies. Mol. Biotechnol. 2010, 45:257-266.
89. Pogue G.P., et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol. J. 2010, 8:638-654.
90. Kuroiwa Y., et al. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat. Biotechnol. 2009, 27:173-181.
91. Kuczewski M., et al. A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnol. J. 2011, 6:56-65.
92. Baer M., et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 2009, 77:1083-1090.
93. Frank D.W., et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis. 2002, 186:64-73.
94. Dharmasena M.N., et al. Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes. Microbiology 2009, 155:2353-2364.
95. Xiao X., et al. Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model. PLoS One 2010, 5:e13047.
96. Wang Q., et al. Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models. Can. J. Microbiol. 2010, 56:1003-1010.
97. Pratt T.S., et al. Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp. Lung Res. 2007, 33:459-481.
98. http://www.cangene.com/.
99. http://www.hgsi.com/.
100. Migone T.S., et al. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 2009, 361:135-144.
101. Mohamed N., et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 2005, 73:795-802.
102. http://www.pharmathene.com/.
103. Vitale L., et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. 2006, 74:5840-5847.
104. Cotter T.W., et al. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect. Immun. 1995, 63:4704-4714.
105. http://www.alopexx.com/.
106. Centers for Disease Control and Prevention (CDC) Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin. Morb. Mortal Wkly. Rep. 2010, 59:299.
107. Garcia-Rodriguez C., et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng. Des. Sel. 2010, 13:1-11.
108. http://www.xoma.com/.
109. http://www.progenics.com/.
110. http://www.medimmune.ca/.
111. Morris S.K., et al. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect. Dis. 2009, 9:106.
112. Centers for Disease Control and Prevention (CDC) A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. Morb. Mortal Wkly. Rep. 2006, 55:209-210.
113. Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis. 2006, 10:193-201.
114. http://www.nabi.com/.
115. Beeler J.A., van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 2009, 63:2941-2950.
116. Rajamanonmani R., et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J. Gen. Virol. 2009, 90:799-809.
117. Shrestha B., et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010, 6:e1000823.
118. Hessell A.J., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge. J. Virol. 2009, 84:1302-1313.
119. Hessell A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
120. Hessell A.J., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-956.
121. Wilson J.A., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287:1664-1666.
122. Shedlock D.J., et al. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010, 401:228-235.
123. Zhu Z., et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 2008, 197:846-853.
124. Wang R., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res. 2008, 80:168-177.
125. Beerli R.R., et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol. J. 2009, 6:224.
126. http://www.talecris.com/.
127. http://www.cslplasma.com/.
128. http://www.bayer.com/.
129. http://www.baxter.com/.
130. Buissa-Filho R., et al. The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus. Infect. Immun. 2008, 76:3321-3328.
131. Shapiro S., et al. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect. Immun. 2002, 70:2598-2604.
132. Chaturvedi A.K., et al. Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin. Diagn. Lab. Immunol. 2005, 12:1063-1068.
133. Cabezas J., et al. Potential of anti-Candida antibodies in immunoprophylaxis. Immunotherapy 2010, 2:171-183.
134. Gigliotti F., et al. Passive intranasal monoclonal antibody prophylaxis against murine pneumocystis carinii pneumonia. Infect. Immun. 2009, 70:1069-1074.
135. Van Wye J.E., et al. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol. 1990, 9:7-18.
136. Douzinas E.E., et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit. Care Med. 2000, 28:8-15.
137. Dalhoff A. Synergy between acylureidopenicillins and immunoglobulin G in experimental animals. Am. J. Med. 1984, 76:91-100.
138. Fomsgaard A., Holder I.A. Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice. APMIS 1993, 101:229-234.
139. Dalhoff A., Brunner H. Mode of interaction between immunoglobulin G and mezlocillin against beta-lactamase producing bacteria. Arzneimittelforschung 1983, 33:1666-1671.
140. Akiyama M., et al. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol. Immunol. 2000, 44:629-635.
141. Felts A.G., et al. Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection. J. Trauma 2000, 49:873-878.
142. Barekzi N.A., et al. Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections. Pharm. Res. 2000, 19:1801-1807.
143. Peterson J.W., et al. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 2006, 74:1016-1024.
144. Murga J.D., et al. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2006, 50:3289-3296.
145. Dickson R.C., et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl. 2006, 12:124-133.